FDA – Diabetes medications containing Saxagliptin and Alogliptin: Drug safety communication – Risk of heart failure
05/04/2016
FDA – Diabetes medications containing Saxagliptin and Alogliptin: Drug safety communication – Risk of heart failure
Leggi
Giallo
Le Breaking News di colore giallo sono relative a notizie dalle agenzie regolatorie o da società scientifiche: nuovi farmaci, ritiri, eventi avversi rilevanti…
FDA – Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function
08/04/2016 http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
Leggi
AIFA – Nota sul farmaco Actos (pioglitazone)
18/03/2016
AIFA – Nota sul farmaco Actos (pioglitazone)
Leggi
AIFA – Nota informativa importante sugli inibitori SGLT2
21/03/2016 http://www.agenziafarmaco.gov.it/it/content/aifa-nota-informativa-importante-sugli-inibitori-sglt2
Leggi
Diabetes in pregnancy
NICE guidelines, January 2016 http://www.nice.org.uk/guidance/QS109
Leggi
AIFA – Gestione del diabete in gravidanza: nuovo standard di qualità del NICE
27/01/2016 http://www.agenziafarmaco.gov.it/it/content/gestione-del-diabete-gravidanza-nuovo-standard-di-qualit%C3%A0-del-nice
Leggi
EMA – Metformin and metformin-containing medicines – Review of metformin-containing medicines started
01/02/2016 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Metoformin_and_ metformin-containing_medicines/human_referral_000397.jsp&mid=WC0b01ac05805c516f
Leggi
FDA approves Integra Omnigraft Dermal Regeneration Matrix to treat diabetic foot ulcers.
January 7, 2016 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm480564.htm
Leggi
Standards of Medical Care in Diabetes – 2016
Diabetes Care 2016;39:S4-S5 http://care.diabetesjournals.org/content/39/Supplement_1
Leggi
FDA Drug Safety Communication: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines
16712/2015
FDA Drug Safety Communication: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines
Leggi